FIELD: pharmaceutics.
SUBSTANCE: invention refers to pharmacology, namely to drugs possessing neurotropic activity. Disclosed is the use of salicin as a drug having neurotropic activity for treating neuroses and psychosis.
EFFECT: using the invention enables treating neuroses and psychosis effectively.
8 cl, 1 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
USE OF ISORHAMNETIN 3-O-β-D-GLUCOPYRANOSIDE, HAVING NEUROTROPIC ACTIVITY | 2024 |
|
RU2833215C1 |
USE OF CYNAROSIDE HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2832839C1 |
USE OF APIGENIN HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2832841C1 |
USE OF OREGANOL A WITH NEUROTROPIC ACTIVITY | 2022 |
|
RU2802871C1 |
USE OF COSMOSIIN HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2833214C1 |
USE OF PATULYTHRIN AS AN ANTIDEPRESSANT | 2022 |
|
RU2802977C1 |
USE OF GAULTERIN AS ANTIDEPRESSANT | 2023 |
|
RU2825385C1 |
ANTIDEPRESSANT, ANXIOLYTIC, NEUROPROTECTIVE AND IMMUNOSTIMULATING AGENT | 2010 |
|
RU2429834C1 |
PHARMACEUTICAL COMPOSITION BASED ON BIS-(N-MONOSUCCINYL-L-SERYL-L-LYSINE) HEXAMETHYLENEDIAMIDE (GSB-106) | 2018 |
|
RU2697254C1 |
ANTIDEPRESSANT FOR CORRECTION OF SIDE EFFECTS FROM NEUROLEPTICS | 2019 |
|
RU2746012C2 |
Authors
Dates
2025-01-10—Published
2023-12-31—Filed